Worldwide, schizophrenia is the leading cause of psychosis, and patients who have the disorder are more likely to pass away from both physical and mental illness. This gives market participants in the worldwide anti-psychotic drug industry the chance to create affordable treatments for this condition. The market for anti-psychotic medications is expanding as a result of the high prevalence and rising incidence of neurological illnesses.
The market for Antipsychotic Medications was estimated at USD 14.54 billion in 2021 and is anticipated to increase at a CAGR of 6.9% from 2022 to 2029, rising from USD 15.50 billion to USD 24.74 billion.
Leading Companies in the Antipsychotic Drugs Industry:
1. AstraZeneca:
AstraZeneca was created in 1999 through the union of the Swedish company Astra with the British company Zeneca Group. The company sells branded medications in a number of important therapeutic categories, including those for gastrointestinal, diabetic, cardiovascular, respiratory, cancer, immunology, and rare disorders. In order to boost its cardiorenal pipeline, AstraZeneca will purchase CinCor Pharma in 2023.
2. Pfizer, Inc.:
American headquarters in New York. Built in 1848. One of the biggest pharmaceutical companies in the world, Pfizer with yearly sales of around $50 billion (excluding COVID-19 product sales). The company used to sell a wide variety of chemicals and healthcare items, but today the majority of its sales come from prescription medications and vaccinations. Arena Pharmaceuticals, Inc., which is in the clinical stages of developing novel therapeutic treatments for the treatment of multiple immuno-inflammatory illnesses, and Pfizer Inc. announced today that the two businesses have entered into a binding agreement under which Pfizer would acquire Arena.